Seek Returns

Illumina (ILMN) Stock Analysis

This is a peer-relative look at Illumina (ILMN): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Illumina (ILMN)
Profile ItemILMN
NameIllumina Inc.
Country/RegionUnited States
GICS SectorHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & Services
Market Capitalization32.23 billion USD
CurrencyUSD
ExchangeNasdaq
Listing DateJuly 28, 2000
Security TypeCommon Stock

Price Performance

Cumulative Growth

ILMN
GSPC
Loading price history…
Illumina (ILMN) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Illumina (ILMN) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Illumina (ILMN) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
Total Return (1Y)79.70%24.62%
Total Return (3Y, Annualized)28.16%20.37%
Total Return (5Y, Annualized)-10.65%-4.02%

Risk Profile

Drawdown History

ILMN
GSPC
Loading price history…
Illumina (ILMN) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Illumina (ILMN) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
Volatility (1Y, Annualized)48.47%66.36%
Beta (5Y)1.460.93
Max Drawdown (5Y)-82.95%-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. ILMN is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
Sharpe Ratio (1Y)1.560.36
Sortino Ratio (1Y)2.250.58

Profitability

ROE (TTM)

Illumina (ILMN) posts ROE of 32.39%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Group distribution
Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Largest peers
LLY
86.02%
ILMN
32.39%
NVS
24.33%
AZN
22.57%
JNJ
20.02%
MRK
5.06%
ABBV
--
Loading chart…
Where Illumina (ILMN) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Illumina (ILMN) keeps 19.72% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

Group distribution
ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Largest peers
LLY
31.90%
ILMN
19.72%
AZN
17.68%
NVS
17.49%
JNJ
16.20%
ABBV
15.67%
MRK
3.64%
Loading chart…
Where Illumina (ILMN) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Illumina (ILMN) turns 20.02% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Group distribution
Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Largest peers
LLY
53.66%
ABBV
39.59%
MRK
35.22%
NVS
34.27%
AZN
29.57%
JNJ
25.74%
ILMN
20.02%
Loading chart…
Where Illumina (ILMN) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
ROE (TTM)32.39%-26.66%
ROA (TTM)8.32%-12.50%
Net Margin (TTM)19.72%0.00%
Operating Margin (TTM)20.02%0.00%
Gross Margin (TTM)67.68%37.87%

Growth

Revenue Growth

Illumina (ILMN) grew revenue -0.66%, in the lower peer quartile. The top line is expanding more slowly than at most peers, which can reflect softer demand, lost share, or weaker pricing.

Loading chart…
Illumina (ILMN): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

No usable EPS growth is available for Illumina (ILMN) this period, so the earnings-momentum read is skipped.

Loading chart…
Illumina (ILMN) doesn't report EPS Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

Growth Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
Revenue Growth (YoY)-0.66%11.45%
Revenue Growth (3Y CAGR)-1.78%9.94%
EPS Growth (YoY)--4.28%
EPS Growth (3Y CAGR)--4.17%

Financial Strength

Current Ratio (MRQ)

Illumina (ILMN) has current ratio of 2.63, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Group distribution
Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10
Largest peers
ILMN
2.63
LLY
1.39
MRK
1.35
JNJ
1.02
AZN
1.01
NVS
0.88
ABBV
0.87
Loading chart…
Where Illumina (ILMN) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Illumina (ILMN) has debt-to-equity ratio of 0.74, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Group distribution
Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Largest peers
NVS
1.29
LLY
1.23
MRK
1.20
ILMN
0.74
AZN
0.66
JNJ
0.55
ABBV
--
Loading chart…
Where Illumina (ILMN) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
Current Ratio (MRQ)2.635.52
Debt / Equity (MRQ)0.740.15
Net Debt / EBITDA0.851.08

Dividends

Dividend Yield (TTM)

Illumina (ILMN) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
NVS
2.88%
ABBV
2.40%
MRK
2.29%
JNJ
1.94%
AZN
1.73%
LLY
0.49%
ILMN
0.00%
Loading chart…
Where Illumina (ILMN) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Illumina (ILMN) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
MRK
343.43%
ABBV
117.35%
NVS
90.46%
JNJ
80.12%
AZN
45.38%
LLY
21.71%
ILMN
0.00%
Loading chart…
Where Illumina (ILMN) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Illumina (ILMN) trades at P/E ratio of 36.68, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Group distribution
Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07
Largest peers
MRK
148.21
ABBV
50.05
LLY
43.95
JNJ
41.92
ILMN
36.68
NVS
31.02
AZN
26.37
Loading chart…
Where Illumina (ILMN) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Illumina (ILMN) trades at 7.10 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Group distribution
Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01
Largest peers
LLY
13.95
ABBV
7.80
ILMN
7.10
JNJ
6.69
MRK
5.37
NVS
5.35
AZN
4.63
Loading chart…
Where Illumina (ILMN) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Illumina (ILMN) trades at 10.30 on P/B ratio, in the higher book-value quartile. The market is paying a premium to book, so stronger ROE, cleaner assets, or a better growth profile need to justify it.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Group distribution
Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Largest peers
LLY
29.96
ILMN
10.30
NVS
8.25
JNJ
8.16
MRK
8.06
AZN
5.59
ABBV
-112.34
Loading chart…
Where Illumina (ILMN) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Illumina (ILMN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: ILMNIndustry group median
P/E Ratio (TTM)36.6826.69
P/S Ratio (TTM)7.107.30
P/B Ratio (MRQ)10.303.25
Free Cash Flow Yield (TTM)2.67%-1.66%